TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers
Brief Summary: A cluster randomized field trial to evaluate the impact that training healthcare workers in healthy feeding practices has on the nutrition and health of children.


Options:
A: Inclusion Criteria:

* Newborn infants with birth weight ≥ 2.500 g and gestational age ≥ 37 weeks were considered eligible for the study.

Exclusion Criteria:

* HIV-positive mothers
* Congenital malformation
* Infants referred to intensive care unit
* Multiple pregnancy.
B: Inclusion Criteria:

* All pregnant women in the last trimester of the gestation.

Exclusion Criteria:

* HIV-positive mothers
* congenital malformation
C: Inclusion Criteria:

* Children with at least one primary tooth present.
* Age 6 months to \<6 years. Children under 6 months of age may be enrolled in the study if at least one primary tooth has erupted.
* Residing in one of the First Nations Communities in the Sioux Lookout Zone or in the Thunder Bay District Area, both located in Northwestern Ontario, Canada.
* Parental consent must be provided. If the parent is not the primary caregiver, a legal guardian or a family member who is the primary care provider must sign the consent form.

Exclusion Criteria:

* Children with ulcerative gingivitis and stomatitis. (These children will be referred for treatment.)
* Children with allergy to colophony (colophonium). Colophonium is found in some cosmetics, creams, sunscreens, pine-oil cleaners, chewing gum, and postage stamp glue. Parents will be asked if the child suffers from this particular allergy.
* No teeth present or stainless steel crowns only.
D: Inclusion Criteria:

* They are not involved in the oral health education
* Ability to understand Persian language Adolescents attending high schools in Qazvin

Exclusion Criteria:

* Does not meet inclusion criteria

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Acceptability of the NuvaRing Among College and Graduate Students
Brief Summary: The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the vaginal ring among female undergraduate or graduate students.


Options:
A: Inclusion Criteria:

* over 18
* student enrolled in college or graduate program
* Not have used the contraceptive patch or oral contraceptives within the last month
* Never have used a contraceptive vaginal ring
* Interested in using hormonal contraceptives, specifically NuvaRing and oral contraceptive pills for next 3 months
* In general good health
* Premenopausal with the ability to menstruate

Exclusion Criteria:

* Known or suspected pregnancy
* Pregnancy within 2 months of trial medication
* Past use of any contraceptive vaginal ring
* Hypersensitivity or allergy to NuvaRing or Oral Contraceptives
* Use of investigational drug within 2 months of start of trial medication
* Use of the contraceptive patch or oral contraceptives within past month
* Use of any injectable contraception within 6 months of trial medication
* Planning pregnancy in next 6 months
B: Inclusion Criteria:

* aged \<25 years requesting OC as their primary method of contraception
* currently sexually active or anticipating sexual activity within the next 30 days
* owns cell phone with text messaging capability

Exclusion Criteria:

* contraindications to combined hormonal contraception per clinic protocol (e.g., hypertension)
* previous participation in this study
C: Inclusion Criteria:

* not currently pregnant
* sexually active with a male partner in the past 6 months OR anticipate being sexually active with a male partner in the next 6 months
* does not intend pregnancy in the next 12 months
* has Internet access and email address

Exclusion Criteria:

* tubal sterilization
* hysterectomy
* partner with vasectomy
D: Inclusion Criteria:

* Client attending for abortion
* Client does not want to have a child at the current time
* Client aged 18 or over
* Client owns a mobile phone
* Client willing to receive simple voice messages relating to contraception from Marie Stopes in Khmer language

Exclusion Criteria:

* Not meeting inclusion criteria
* Declined to participate

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trauma-focused Cognitive-behavioural Therapy for Children: A Study of Process and Outcome.
Brief Summary: The purpose of this study is to determine whether Trauma focused cognitive behavioral therapy (TF-CBT)is more effective in the treatment of traumatized youth than treatment as usual(TAU).


Options:
A: Inclusion Criteria:

Participants, both male and female, aged between 18 and 25, whom;

* have experienced CSA before the age of 16
* exhibit PTSD symptomology
* ensure PTSD symptomology is present for over three-months and primarily derived from pre-16 aged trauma
* be available for treatment-sessions on a weekly basis for up to 16-sessions - have good understanding of the English language to avoid language barriers/additional time spent with interpreters
* if taking medication, this will have been stable for a period of at least 2-months prior to therapy
* EMDR is the sole treatment for PTSD from baseline until follow-up to avoid conflict of interest

Exclusion Criteria:

Participants exhibiting;

* significant psychiatric comorbidity
* comorbid psychotic disorder
* bipolar disorder type 1
* alcohol or drug dependence
* acute suicide risk, acute PTSD from trauma within the past 6 months
* PTSD focused treatment within the past 3 months or scheduled to begin another form of PTSD treatment will be excluded
* those currently participating in research or have recently participated in conflicting research
B: Inclusion Criteria:

* Children between the age of 10-18
* referred to a guidance clinic
* who have experienced trauma
* present with PTSD reactions
* participants and the primary caretaker must be able to speak Norwegian.

Exclusion Criteria:

* Severe psychosis
* Severe mental retardation.
* The youth must not have had severe conduct disorders previous to the trauma experience
C: Inclusion Criteria:

* Women Veterans who experienced MST
* Diagnosed with PTSD related to MST
* Insomnia
* Willing to participate in either TCTSY or CPT study intervention

Exclusion Criteria:

* Schizophrenia with significant psychotic symptoms
* Current, active suicidal intent or plan
* Current substance abuse or dependence
* Certain medical conditions that can contribute significantly to psychiatric symptoms, including:

  * poorly controlled hypo/hyperthyroidism
  * kidney or liver failure
* Dementia
* Moderate or severe traumatic brain injury (TBI) or other cognitive impairment sufficient to interfere with ability to give informed consent
* Pain due to acute injury (\<3 months), post-surgical pain (\<3 months) or pain due to malignancy; pain related to injury and surgery are excluded to reduce risk of exacerbating underlying injury
* Receiving mental health treatment outside of the VA
* Ongoing participation in mental health treatment at odds with study intervention (For Example: yoga, trauma-focused treatment)
D: Inclusion Criteria:

* survivor of sexual violence
* mental health symptom severity cut-off
* functional impairment cut-off

Exclusion Criteria:

* active suicidality
* not living in the study site

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants: The Canadian Oxygen Trial (COT)
Brief Summary: Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pulse oximetry (SpO2)of 85-89% compared with 91-95%, from the day of birth until the baby's first discharge home, increase the probability of survival without severe neurosensory disability to a corrected age of 18 months?


Options:
A: Inclusion Criteria:

Preterm infants less than 33 weeks (23+0 to 32+6 weeks)

• Receiving invasive or non-invasive mode of respiratory support

Exclusion Criteria:

* Infants more than or equal to 33 weeks
* Preterm infants with congenital anomalies
* Infants on a non-conventional mode of invasive or non-invasive ventilation
B: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
C: Inclusion Criteria:

* Preterm infants less than 31 weeks completed gestation at birth requiring mechanical ventilation and admitted to King's NICU in the first 48 hours after birth

Exclusion Criteria:

* Preterm infants above 31 weeks completed gestation or term born infants
* Infants with major congenital abnormalities
D: Inclusion Criteria:

* Gestational age 23 0/7 - 27 6/7 weeks
* Postnatal age \< 24 hours

Exclusion Criteria:

* Infant not considered viable (decision made not to administer effective therapies)
* Dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* Known or strongly suspected cyanotic heart disease
* Persistent pulmonary hypertension, e.g. associated with pulmonary hypoplasia
* Unlikely to be available for long-term follow-up

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants: The Canadian Oxygen Trial (COT)
Brief Summary: Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pulse oximetry (SpO2)of 85-89% compared with 91-95%, from the day of birth until the baby's first discharge home, increase the probability of survival without severe neurosensory disability to a corrected age of 18 months?


Options:
A: Inclusion Criteria:

* Infants \< 28wks gestation

Exclusion Criteria:

* Infants \> 28wks gestation
B: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
C: Inclusion Criteria:

* Gestational age 23 0/7 - 27 6/7 weeks
* Postnatal age \< 24 hours

Exclusion Criteria:

* Infant not considered viable (decision made not to administer effective therapies)
* Dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* Known or strongly suspected cyanotic heart disease
* Persistent pulmonary hypertension, e.g. associated with pulmonary hypoplasia
* Unlikely to be available for long-term follow-up
D: Inclusion Criteria:

* Inborn
* Gestation age 24 0/7 to 34 6/7
* Need for active resuscitation

Exclusion Criteria:

* Prenatally diagnosed cyanotic congenital heart disease
* Non-viable newborns
* Precipitous delivery and resuscitation team not present in the delivery room to initiate resuscitation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain
Brief Summary: The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies.


Options:
A: Inclusion Criteria:

* Chronic Uncontrolled Pain That Required Stronger Opioid Therapy Than They Have Been Taking
* Histologically Confirmed Solid Cancer
* Aged Over 18 Years
* Admitted in a Palliative Cancer Care Unit

Exclusion Criteria:

* Uspected to Have Narcotic Abuse, Clinically Relevant CO2 Retention or Had an Active Skin Disease
* Inability to swallow oral medication, and impaired sensory or cognitive function
* Patients who had an active infection, uncontrolled central nervous system involvement, or on antitumor therapy of any kind
B: Inclusion Criteria:

* instrumental and clinical diagnosis of every malignant neoplasm
* presence of pain with a neuropathic component in the opinion of the physician
* presence of pain \>=4(NRS)
* PS ECOG \<3
* written informed consent

Exclusion Criteria:

* serum creatinine \>2mg/ml or creatinine clearance \<40 ml/min
* mild or severe hepatic insufficiency
* iatrogenic neuropathy caused by chemotherapeutic agents
* previous allergic reactions to oxycodone and pregabalin
* pregnancy or breastfeeding
C: Inclusion Criteria:

* Diagnosis of histologically or cytologically proven solid tumor with or without metastasis
* Receiving treatment at UF Health Cancer Center for outpatient pain management with an opioid

Exclusion Criteria:

* Undergone surgery within the last three months or are scheduled to undergo surgery during the study period (4 weeks)
* Documented psychiatric or neurological condition that would interfere with study participation
* Liver transplant
* Allergic to opioids
D: Inclusion Criteria:

1. Adult men and women aged 19 years or more
2. Patients with cancerous pain who are hospitalized or scheduled for hospitalization at Screening and not planned to be discharged during the study
3. Patients with mean moderate to severe pain over the past 7 days at Screening as verbally confirmed (NRS 4 or higher)
4. Subjects who voluntarily signed the Informed Consent Form for the study
5. Subjects who are capable of understanding details of the study and verbal communication on pain intensity

Exclusion Criteria:

1. Patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to Screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour)
2. Patients with a medical history of hypersensitivity to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics
3. Patients who have contraindications and cautions when study drugs administered.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Efficacy of Cranberry Juice in the Prevention of Urinary Tract Infections in Children - Randomized, Placebo Controlled Multi-Center Study
Brief Summary: The objective of the study is to determine whether recurrences of urinary tract infection in children can be prevented with cranberry juice.


Options:
A: Inclusion Criteria:

* Recent confirmed urinary tract infection, diagnosed in Oulu University Hospital or Oulu Health Care Center
* Age 1-16 years

Exclusion Criteria:

* Continuous antimicrobial prophylaxis
* Age \< 12 months or \> 16 years
* Severe congenital kidney or other urinary tract anomaly in ultrasound
B: Inclusion Criteria:

* Patient is cared for by the department of the Gynecology at the Nîmes Unversity Hospital
* The patient is programmed for surgery with placement an indwelling catheter for 48 hours with a sterile urinary cytobacteriologic exam at inclusion

Exclusion Criteria:

* the urinary cytobacteriologic exam at inclusion is positive
* the patient is taking antivitamin K
* the patient is taking antibiotics
* history of urolithiasis
* the patient refuses to participate
* the patient is pregnant or nursing
* the patient is not associated with a social security system (no insurance)
* the patient is under guardianship
C: Inclusion Criteria:

* Urinary Tract Infection 0-2 months priorly

Exclusion Criteria:

* Antibiotic Prophylaxis
D: Inclusion Criteria:

* At least one UTI within 12 months prior to study entry
* Premenopausal
* Agree to avoid all foods that contain plants from the genus Vaccinium (related to cranberries) for the duration of the study

Exclusion Criteria:

* Anatomic abnormalities of the urinary tract
* History of kidney stones
* Bacteria in the urine (bacteriuria)
* Use of prophylactic antibiotics within 7 days prior to study entry
* Use of investigational drugs within 30 days prior to study entry
* Current use of warfarin
* Diabetes
* Cancer. Participants with skin cancer are not excluded.
* Allergy or intolerance of cranberry products
* Symptomatic vaginitis
* Pregnant or breastfeeding

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Training and Antioxidant Treatment on Circulating Markers of Oxidative Stress and Skeletal Muscle mRNA Expression
Brief Summary: The aim of the study is to compare the effects of an intensive 4 weeks exercise training program with or without additional treatment with antioxidants. 16 volunteers are included into the study and randomized into a treatment (n=8,Vitamine E 400 IU od + vitamine C 1g twice daily) and a non-treatment (n=8, training only) group. Before and after the training program, skeletal muscle biopsies will be taken to measure PGC-1alpha and PPARgamma mRNA expression. In addition before and after the training program individuals will have the following measurements: body weight, waist circumference, body fat content (DEXA scan), euglycemic-hyperinsulinemic clamps, ergospirometer (VO2 max), routine laboratory measurements, serum malondialdehyde concentrations.


Options:
A: Inclusion Criteria:

* trained at least five sessions per week with 90 to 120 min per session
* had an experience of more than 3 years in Olympic weightlifting

Exclusion Criteria:

* use any antioxidant (e.g., vitamin E, A, C etc..) or anti-inflammatory during the experimentation period and one month before
* had injuries during the experimentation period and one month before
B: Inclusion Criteria:

* FSHD patients will be recruited on the basis of:

  * The number of repeat units (4 to 9)
  * FSHD patients with a positive family history for FSHD
  * Not confined to a wheelchair
  * No smokers
  * No associated co-morbidity (cardiac or pulmonary disease, diabetes etc.)
  * No Medications or nutritional supplementation (vitamins and/or antioxidants) at the time of the study
  * No HIV positive

Exclusion Criteria:

* No consent form
C: Inclusion Criteria:

a) recreationally trained as evidenced by their maximal oxygen consumption levels (VO2max \>45 ml/kg/min), b) were engaged in systematic exercise at least three times/week for ≥12 months), c) non-smokers, d) abstained from any vigorous physical activity during the study, e)abstained from consumption of caffeine, alcohol, performance-enhancing or antioxidant supplements, and medications during the study.

Exclusion Criteria:

a) a known NAC intolerance or allergy, b) a recent febrile illness, c) history of muscle lesion, d) lower limb trauma
D: Inclusion Criteria:

* Must be able to swallow tablets
* signed informed consent
* no concommitant medication
* male
* age between 25 - 35 years

Exclusion Criteria:

* drug, tobacco or alcohol abuse
* any chronic disease
* any acute or chronic inflammatory disease as determined by a leucocyte count \> 7000 Gpt/l, C-reactive protein (CrP) \> 5.0 mg/dl or clinical signs of infection
* systolic blood pressure (SBP) \> 140mmHg and diastolic blood pressure (DBP) was \> 85mmHg
* cardiovascular or peripheral artery disease
* thyroid dysfunction

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
Brief Summary: Aims:

1. To develop a food supplement containing a health-promoting probiotic bacteria (B. lactis BB12) and xylitol to be administered with a novel soft, possibly occlusion-friendly pacifier.
2. Test in a clinical study how feasible the method is and to study how the intervention affects caries occurrence.

Main hypothesis:

The administration of B. lactis BB12 and xylitol affects beneficially the dental health of the child.


Options:
A: Inclusion Criteria:

* Children who's parents have signed and returned informed consent form

Exclusion Criteria:

* Any eating disorder
* Refuse to continue
B: Inclusion Criteria:

* age 25-80
* at least one caries lesion in year prior to enrollment
* at least 12 teeth without crowns
* no allergies to xylitol or aspartame
* anticipate remaining in area for 3 years

Exclusion Criteria:

* 10 or more caries lesions in year prior to enrollment
* currently receiving long-term antibiotic therapy
* history of head and neck radiation
C: Inclusion Criteria:

1. mothers presenting with active dental decay or restorations within the past year (high caries risk)
2. mothers who are the primary caregivers for their child
3. healthy children without systemic disease aged 6 months to two years
4. Infants younger than 6 months who have one or more teeth present

Exclusion Criteria:

1. mother or child with systemic disease
2. antibiotics or medications taken within the previous 3 months that may alter oral flora and saliva flow for mother or child
3. children who primarily receive care in a daycare center or by a caregiver other than the mother
D: Inclusion Criteria:

* The infant is healthy
* The family agrees to use the novel slow-release pacifier
* The infant starts to use the pacifier before the age of 3 months

Exclusion Criteria:

* The child is not healthy

Answer: D